Medications for Opioid Use Disorder (MOUD) - Useful Links

Justice Community Overdose Innovation Network (JCOIN) Webinars

Expanding Access to Methadone Treatment for Opioid Use Disorder in Carceral Settings

Description: This webinar provided an overview of the updated final rules of 42 CFR Part 8 and how they affect methadone dispensation in carceral settings. (45 min)

Key Barriers and Facilitators for Medications to Treat Opioid Use Disorders in U.S. Jails

Description: This webinar presented findings from the national study, including the identification of 10 OUD best practices that were consistently referenced in treatment and practice guidelines recommended by a variety of federal agencies and national organizations, and were grounded in the scientific literature. (56 min)

Strategies to Reduce Recidivism and Prevent MOUD Diversion in Jails and Prisons

Description: Panelists will discuss the benefits of implementing MOUD programs in correctional facilities, including the impact MOUD has had on reducing recidivism rates. Panelists will also discuss promising practices in program design to help limit medication diversion and provide guidance for correctional professionals and lawmakers as they consider implementing MOUD treatment in jails and prisons. (52 min)

Treatment Considerations in the Age of Fentanyl

Description: Presenters discussed practical clinical practice-based guidance on treating opioid use disorder in the age of fentanyl, the use of medications for opioid use disorder (MOUD) in the treatment of individuals using fentanyl and other considerations and challenges. (83 min)

Medications for Opioid Use Disorder in Criminal Justice Settings

Description: This webinar discussed the FDA-approved medications for opioid use disorder (MOUD), how addiction is a chronic neurobehavioral disorder, that MOUD works by attenuating positive and negative reinforcement, and the effectiveness of MOUD for individuals with an opioid use disorder, and specifically for those in jails and prisons. (56 min)

PODCASTS: ACED IT (see:https://acedit.podbean.com/)

Medication for Substance Use Disorders in Prisons and Jails

Description: To educate correctional staff and administrators about medication for SUD/OUD in prisons, we selected three articles that highlight what these treatments are, how jails/prisons can partner with community providers to offer them, and what barriers and facilitators to MAT/MOUD implementation institutions may want to consider before adding this type of treatment to their roster of services. (14 min)

Substance Use Disorder in Prisons and Jails

Description: Although there is a lot we could talk about related to SUD in carceral settings, in this episode we will cover three key topics that came up frequently during our project interviews: fentanyl, K2, and drug testing. These three issues challenge correctional staff; their level of understanding regarding fentanyl and K2, specifically, is generally very limited. We provide today’s science on these topics and offer some advice on in-custody drug testing, too. (15 min)

Race & Medication for Opioid Use Disorder (MOUD)

Description: This episode looks at research that examines the relationship between race and the use of medication for opioid use disorder (MOUD). The researchers also look at other factors that might mediate this relationship. Findings suggest a big gap, but the researchers offer recommendations to help close this gap so everyone can access and receive MOUD equally. (11 min)

• WEBSITE:Medications for Opioid Use Disorder (MOUD) Study (CDC) 

• WEBSITE:Linking People with Opioid Use Disorder to Medication Treatment (CDC)

• DOCUMENT: How the Drug Enforcement Administration Can Improve Access to Methadone in Correctional Facilities and Save Lives (Johns Hopkins Bloomberg School of Public Health)

• DOCUMENT: Providing Methadone in Jails and Prisons: An Explanation of a New Approach to Increase Access to Methadone in Carceral Settings (Johns Hopkins Bloomberg School of Public Health)

• DOCUMENT: Brief FAQ on Methadone Use to Treat Opioid Use Disorder (OUD) in Carceral Settings Using the Hospital/Clinic Designation (Johns Hopkins Bloomberg School of Public Health)

• FORUM: Expanding Methadone Access in Correctional Facilities (Johns Hopkins Bloomberg School of Public Health)

  Description: A recording of the forum recently hosted by the Johns Hopkins Center for Mental Health and Addiction Policy and the White House Office of National Drug Control Policy covering the Substance Abuse & Mental Health Services Administration’s rules and guidance on methadone use in correctional facilities (1 hour, 7 min)

•  DOCUMENT: TIP 63: Medications for Opioid Use Disorder (For Healthcare and Addiction Professionals, Policymakers, Patients, and Families) (SAHMSA)

•  WEBSITE:Recovery is Possible: Treatment for Opioid Addiction (CDC)

•  WEBSITE:Treatment options - Opioid Use Disorder (CDC)

•  WEBSITE:Recovery is Possible: Know the Options  (CDC)

•  DOCUMENT: What You Need to Know About Treatment and Recovery (CDC)

•  DOCUMENT: Cultivating Law and Medicine Partnerships to Support Justice-Involved Individuals with Substance Use Disorders (AAAP)

• DOCUMENT: Medications for Opioid Use Disorder Save Lives (National Academies Press)

•  DOCUMENT:Overdose Prevention and Response Toolkit (SAHMSA)

• WEBSITE: Preventing Opioid Use Disorder (CDC) (CDC

• WEBSITE: Buprenorphine (SAHMSA)

•  DOCUMENT: The Facts About Buprenorphine (SAHMSA)

• WEBSITE:Methadone (SAHMSA)

• TRAINING: SFDPH Overdose Prevention Training Series (San Francisco DPH)

• WEBSITE: Medications to Treat Opioid Use Disorder Research Report (NIDA)

VIDEO: Medications for Opioid Use Disorder (3 min, 42 sec) (NIDA)

• WEBSITE: Overdose Reversal Medications (NIH)

• WEBSITE: What is naloxone? (NIH)

• WEBSITE: Naloxone (California Department of Public Health)

• WEBSITE: Over the Counter Naloxone (California Department of Public Health)

• WEBSITE: Overdose Prevention (San Francisco AIDS Foundation)

• WEBSITE: Reverse Opioid Overdose to Prevent Death (Centers for Disease Control)

• WEBSITE: 5 Things to Know About Naloxone (Centers for Disease Control)

• WEBSITE: Lifesaving Naloxone(Centers for Disease Control)

• COMMENTARY: Time for Honest Discussions About Naloxone (Medscape and the Centers for Disease Control)

  Description: This video is from 2019. Jerome M. Adams and Debra Houry discuss naloxone. (8 min, 25 sec)

• DOCUMENT: What You Need to Know About Naloxone (Centers for Disease Control)

• DOCUMENT: How and When to Use Naloxone for an Opioid Overdose (Centers for Disease Control)

• TRAINING: Talking About Naloxone (Centers for Disease Control)

  Description: This training focuses on how to talk with patients and their families, friends, and caregivers about naloxone. Mini-Modules:

1. Assessing Risk Factors for Opioid Overdose

2. Engaging Patients in a Conversation about Naloxone

3. Reducing Stigma Surrounding Naloxone

• DOCUMENT: Naloxone: How to Save a Life with Naloxone

• DOCUMENT: SAMHSA: Overdose Prevention and Response Toolkit

• WEBSITE: https://www.cdc.gov/stop-overdose/naloxone-faq/index.html

• PODCAST: Lifesaving Naloxone (7 min, 15 secs)

• DOCUMENT: Reversing Opioid Overdoses with Lifesaving Naloxone

• WEBSITE: https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/opioid-overdose-reversal-medications

• DOCUMENT: Naloxone: The Opioid Reversal Drug That Saves Lives

• WEBSITE: https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/opioid-overdose-reversal-medications/over-the-counter-naloxone-faqs

• WEBSITE: https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/naltrexone

• WEBSITE: SFDPH: About Naloxone

• TRAINING: SFDPH Overdose Prevention Training Series

• WEBSITE: https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose

• WEBSITE: Medications to Treat Opioid Use Disorder Research Report

• VIDEO: How Naloxone Saves Lives in Opioid Overdose (5 min, 39 sec)

CalAIM (California Advancing and Innovating Medi-Cal) - Useful Links

• WEBSITE:What is CalAIM? (California Department of Health Care Services) 

• VIDEO: CalAIM | Our Journey to a Healthier California for All (1 min, 50 sec) (CalAIM)

• VIDEO: California Advancing and Innovating Medi-Cal (CalAIM) (18 min, 15 sec) (CalAIM)

• WEBSITE: California Immigrant Policy Center - Resource Page

  Description: A multitude of resources on immigrants’ rights, in both English and Spanish

• WEBSITE: Free legal services for workers in California (Legal Aid at Work)

• DOCUMENT:Employment Rights of Undocumented Workers (Legal Aid at Work)

• NEWS ARTICLE: California expands health insurance to all eligible undocumented adults (Cal Matters)

• WEBSITE: Benefits and Resources for Undocumented Workers (Employment Development Department, State of California)

• DOCUMENT:Overview: Public Benefits for Noncitizens in California (Immigrant Legal Resource Center)

• WEBSITE: Overview of Immigrant Eligibility for Federal Programs(National Immigration Law Center)

• WEBSITE: Overview of Immigrant Eligibility for Federal Programs (Table) (National Immigration Law Center)

• DOCUMENT:Undocumented Workers’ Guide to Applying for California Disability Insurance & Paid Family Leave(Legal Aid at Work)

• WEBSITE: Under what circumstances may a non-citizen by eligible for SSI? (Social Security Administration)

• NEWS ARTICLE: In Act of Civil Disobedience, Activists Set Up Safe Drug Consumption Site in San Francisco (KQED)

• NEWS ARTICLE: California debates opening supervised sites for people to use drugs (National Public Radio)

• NEWS ARTICLE: What’s behind Newsom’s safe injection sites veto? (Cal Matters)

• NEWS ARTICLE: Governor Newsom Vetoes Bill for Drug-Injection Sites in California (New York Times)

• NEWS ARTICLE: Understanding Supervised Injection Sites (Syracuse University)

• NEWS ARTICLE: ‘This is not the end’: L.A. advocates say veto doesn’t shut door to safe injection sites (Los Angeles Times)

• WEBINAR: Making PrEP accessible: Updates on long-acting injectable options (International AIDS Society)

  Description: The webinar was hosted by IAS and provided the latest updates on long-acting injectable PrEP, including science and research emerging from recent conferences and the results from HPTN 083 and 084.  Participants also heard a civil society perspective on the evolving PrEP landscape, as well as on-the-ground approaches to increase access to long-acting PrEP. (91 min)

• ARTICLE: Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96% (Advocate)

• ARTICLE: WHO recommends long-acting cabotegravir for HIV prevention (World Health Organization

• WEBSITE: What is Apretude? (ViiV Healthcare)

• ARTICLE: FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention (United States Food and Drug Administration)

• VIDEO: Health Centers on the Front Lines Podcast: Long-Acting Injectable PrEP & HIV Treatment (20 min, 33 sec) (Target HIV)

  There is a briefer version of this video: Long-Acting Injectable PrEP and HIV Treatment Microlearning (5 min, 48 sec) (Target HIV)

• ARTICLE: Injectable PrEP Is Here. What Does This Mean for You? (San Francisco AIDS Foundation)

• DOCUMENT: Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention (World Health Organization)

PEP for HIV

• WEBSITE: Post Exposure Prophylaxis (PEP) (NIH) 

• WEBSITE: What is PEP? (Planned Parenthood)

• WEBSITE: PEP Information for Patients (Los Angeles County Division of HIV and STD Programs)

DoxyPEP

• WEBSITE: DoxyPEP for Bacterial STI Prevention (CDC)

• DOCUMENT: DoxyPEP for STI Prevention (Los Angeles DPH)

• DOCUMENT: Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024

• ARTICLE: Doxycycline for STI Prevention: Highly Effective, Minimal Drug Resistance (UCSF)

• WEBSITE: DoxyPEP Overview (CDC)

• WEBSITE: Doxy PEP for Bacterial STI Prevention (CDC)

• DOCUMENT: CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024 (CDC)

• ARTICLE: Doxycycline for STI Prevention: Highly Effective, Minimal Drug Resistance (UCSF)

• WEBSITE: Preventing STIs with DoxyPEP (CDC)

• DOCUMENT: Guidelines for HIV post-exposure prophylaxis (World Health Organization)

• VIDEO: What Is Post Exposure Prophylaxis (Also, Known As PEP)?  (1 min, 32 sec) (Planned Parenthood)

• WEBSITE: What is Hepatitis C? (San Francisco AIDS Foundation)

• DOCUMENT: Hepatitis C (Fact Sheet) (Centers for Disease Control)

• DOCUMENT:Hepatitis C and injection drug use (Fact Sheet) (Centers for Disease Control)

• WEBSITE: Hepatitis C Basics (Centers for Disease Control)

• WEBSITE: Hepatitis C Basics (United States Department of Health and Human Services)

• WEBSITE:Hepatitis C (World Health Organization)

• WEBSITE: Signs and Symptoms of Hepatitis C (Centers for Disease Control)

• WEBSITE: Hepatitis C Prevention and Control (Centers for Disease Control)

• WEBSITE: Testing for Hepatitis C (Centers for Disease Control)

• WEBSITE: Treatment of Hepatitis C (Centers for Disease Control)

• WEBSITE: Hepatitis C (National Institutes of Health)

• WEBINAR: Reentry Research – Mitigating the Risk during Reentry for People with Substance Use Disorders (JCOIN)

  Description: The risk of overdose death significantly increases during the first two weeks during entry into the community. In this webinar, presenters will discuss the latest research, science, and innovation around mitigating risk during reentry for people with opioid use disorders. Topics covered will include medications for opioid use disorder (MOUD), behavioral interventions, and establishing linkages to community-based support services. (86 min)

• WEBINAR: Reentry Best Practices for People with Opioid Use Disorder (JCOIN)

  Description: This webinar discussed the latest research, science, and innovation around mitigating risk during reentry for people with opioid use disorders. Topics covered will include medications for addiction treatment (MAT), behavioral interventions, and establishing linkages to community-based support services. (82 min)